Lexeo Therapeutics, Inc.: Paradigm Biocapital Advisors LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Paradigm Biocapital Advisors LP amended its Schedule 13G filing for Lexeo Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-128311. The filing reflects the investment advisor's position in the clinical-stage gene therapy developer, though the amended document did not disclose a change in share count in the headline details. Schedule 13G amendments are typically filed by institutional investors to reflect quarterly position changes or passive stake adjustments above the 5% threshold. The update matters because it signals Paradigm Biocapital's continued institutional interest in Lexeo, a company developing gene therapies for cardiovascular and neurological diseases. Investors will watch for the specific share totals and any percentage change in the full filing, along with Lexeo's upcoming clinical trial updates and cash runway disclosures.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Lexeo Therapeutics, Inc., Paradigm Biocapital Advisors LP